Results 31 to 40 of about 342 (145)

Quantitative Evaluation of Nemolizumab Pharmacokinetics and Efficacy in Prurigo Nodularis: A Population Pharmacokinetics and Model-Based Meta-analysis Approach

Dermatology and Therapy
Introduction Nemolizumab is a humanized monoclonal antibody targeting interleukin-31 receptor A. It has shown efficacy in treating patients with prurigo nodularis (PN).
Tomoki Takechi, Junya Shimizu, Kenji Kabashima, Ichiro Ieiri   +3 more
doaj   +1 more source

Comparative safety profiles of dupilumab and nemolizumab in prurigo nodularis: an indirect META-analysis to inform clinical decision-making

Frontiers in Medicine
BackgroundPrurigo nodularis (PN), a chronic inflammatory skin disease with significant disease burden, lacks effective therapies. Dupilumab (IL-4Rα inhibitor) and nemolizumab (IL-31 receptor antagonist) show efficacy in trials but have heterogeneous ...
Wenzhe Feng, Dongyang Wang, Kaiyue Tan, Xiaojie Zhang   +3 more
doaj   +1 more source

Advances in systemic treatment for adults with moderate-to-severe atopic dermatitis

Dermatologica Sinica, 2019
Atopic dermatitis (AD) is generally considered a T-helper type 2-dominated disease. Adult AD is often more severe and less manageable by topical therapies and may require systemic immunosuppressants that bear notable side effects and organ toxicities ...
Yung-Tsu Cho, Chia-Yu Chu
doaj   +1 more source

Interleukin-31 as a Clinical Target for Pruritus Treatment

Frontiers in Medicine, 2021
In recent years, the published literature has suggested the key involvement of the cytokine interleukin-31 (IL-31) in the symptomatology of pruritus, and both IL-31 and its receptor have become potential therapeutic targets for a range of pruritic ...
Kenji Kabashima, Hiroyuki Irie
doaj   +1 more source

Serum‐Proteomic Profiling Reveals Distinct Atopic Dermatitis Severity‐Linked Signatures

Allergy, EarlyView.
This study aimed to identify a set of serum biomarkers that robustly distinguish prespecified severe from mild atopic dermatitis groups. Serum proteomic profiling distinguishes severe from mild atopic dermatitis, revealing an epithelial enriched severity footprint linked to LDH‐associated tissue injury and Th2/Th22 inflammation.
Jag S. Lally, Takeshi Yoshida, Shan Gao, Xueya Cai, Donald Y. M. Leung, Lisa A. Beck, Anna De Benedetto   +6 more
wiley   +1 more source

436 Nemolizumab monotherapy was associated with significant improvements in prurigo activity score in adult patients with moderate-to-severe prurigo nodularis: results from a phase 3 trial (OLYMPIA 2)

, 2023
Prurigo nodularis (PN) or chronic nodular prurigo is a debilitating, and severely pruritic neuroimmune skin disease, predominantly characterized by the presence of multiple pruriginous nodules symmetrically distributed in large areas of the trunk and ...
Franz J Legat, Luigi  Naldi, Alan Fleischer, Fleischer, Alan, Shawn G Kwatra, Legat, Franz J, Silverberg, Jonathan I, Jabbar-Lopez, Zarif, Gharib, Rola, Jonathan I Silverberg, Reich, Adam, Piketty, Christophe, Dagmar Simon, Ständer, Sonja, Paul, Carle, Simon, Dagmar, Adam Reich, Faiz Ahmad, Zarif Jabbar-Lopez, Vivian T Laquer, Christophe Piketty, Gil Yosipovitch, Laquer, Vivian T, Naldi, Luigi , Kwatra, Shawn G, Carle Paul, Sonja Ständer, Rola Gharib, Ahmad, Faiz, Yosipovitch, Gil   +29 more
core   +1 more source

Validation of the Peak Pruritus Numerical Rating Scale as a Patient-Reported Outcome Measure in Prurigo Nodularis

Dermatology and Therapy, 2023
Introduction Validated patient report tools for quantifying patient experiences of itch in prurigo nodularis (PN) are limited. This study aimed to evaluate the validity of the 11-point peak pruritus numerical rating scale (PP NRS) as a single-item ...
Shawn G. Kwatra, Danielle Rodriguez, Carla Dias-Barbosa, Ismail Budhiarso, Fatoumata Fofana, Margaret Vernon, Sylvie Gabriel, Christophe Piketty, Jorge Puelles   +8 more
doaj   +1 more source

Understanding the Type 2 Immunity: An Evolving View Beyond Allergic Diseases

Allergy, EarlyView.
ABSTRACT Type 2 (T2) immunity is classically associated with defense against helminths and environmental threats, from a physiological perspective, and with allergies and eosinophilic inflammatory diseases, in a pathological sense. However, growing evidence reveals that T2 pathways also support other essential homeostatic functions, including tissue ...
Rodrigo Jiménez‐Saiz, Salvador Iborra, Carlos Blanco, Ruperto González‐Pérez, Emilio Nuñez‐Borque, Can Zeyneloglu, Huseyn Babayev, Ozlem Göksel, Tuncay Göksel, Musa Khaitov, Dmitry Kudlay, Yadong Gao, Mustafa Sevim, Marie‐Charlotte Brüggen, Oral Alpan, Ming Wang, Luo Zhang, María J. Torres, Mohamed Shamji, Mübeccel Akdis, Kari C. Nadeau, Ismail Ogulur, Cezmi A. Akdis   +22 more
wiley   +1 more source

Optimal Use of Jak Inhibitors and Biologics for Atopic Dermatitis on the Basis of the Current Evidence

JID Innovations, 2023
Recently, Jak inhibitors such as baricitinib, upadacitinib, and abrocitinib were approved for the treatment of atopic dermatitis (AD) in addition to biologics, including dupilumab, tralokinumab, and nemolizumab. The increase in treatment options can be a
Masahiro Kamata, Yayoi Tada
doaj   +1 more source

Image_2_Safety and Efficacy of Nemolizumab for Atopic Dermatitis With Pruritus: A Systematic Review and Meta-Regression Analysis of Randomized Controlled Trials.tif

, 2022
BackgroundNemolizumab is deemed as a promising drug for atopic dermatitis (AD) patients with pruritus.ObjectiveThis study aimed to evaluate the efficacy of nemolizumab in treating patients with AD and the association between the dosage or regimen of ...
Fengxia Hu (5745692), Xiaojing Kang (3931046), Maoli Dan (12459273), Qian Wang (32718), Yongzhen Hong (12459282), Junqin Liang (12459270), Yingbing Sang (12459276), Kailibinuer Abulikemu (12459279)   +7 more
core   +1 more source